Montelukast in 2 atopic patients with intolerance to nonsteroidal anti-inflammatory drugs and paracetamol: 5-year follow-up.

1. Kumar A, Teuber SS, Gershwin ME. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol. 2006:140:185-98. 2. Fergusson D, Hutton B, Sharma M, Tinmouth A, Wilson K, Cameron DW, Hebert PC. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion (Paris). 2005:45:1640-57. 3. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997:126:721-30. 4. Mutasim DF, Sheth PB. An eruption secondary to intravenous immunoglobulin therapy. Cutis. 2002;69:35-6,38. 5. Barbaud A, Trechot P, Granel F, Lonchamp P, Faure G, Schmutz JL, Bene MC. A baboon syndrome induced by intravenous human immunoglobulins: report of a case and immunological analysis. Dermatology. 1999:199:258-60. 6. Uyttendaele H, Obadiah J, Grossman M. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy. J Drugs Dermatol. 2003:2:337-41. 7. Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006:142:213-7. 8. Maetzke J, Sperfeld AD, Scharffetter-Kochanek K, Sunderkotter C. Vesicular and bullous eczema in response to intravenous immunoglobulins (IVIG). Allergy. 2006:61:145-6. 9. Crosti C, Lodi A. Pompholyx: a still unresolved kind of eczema. Dermatology. 1993:186:241-2. 10. Yokozeki H, Katayama I, Nishioka K, Kinoshita M, Nishiyama S. The role of metal allergy and local hyperhidrosis in the pathogenesis of pompholyx. J Dermatol. 1992:19:964-7.